Evolus, Inc. (NASDAQ:EOLS) shot up 5.4% during trading on Monday . The company traded as high as $4.83 and last traded at $4.47. 815,575 shares were traded during trading, an increase of 2% from the average session volume of 796,056 shares. The stock had previously closed at $4.24.
A number of research firms have recently commented on EOLS. HC Wainwright lowered their target price on Evolus from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, December 17th. ValuEngine downgraded Evolus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 1st. Zacks Investment Research downgraded Evolus from a “buy” rating to a “hold” rating in a research report on Tuesday, October 13th. Finally, Mizuho reiterated a “hold” rating and set a $5.00 target price on shares of Evolus in a research report on Tuesday, September 22nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. Evolus has a consensus rating of “Hold” and a consensus price target of $8.75.
The company has a fifty day moving average of $3.82 and a two-hundred day moving average of $3.77. The company has a market cap of $172.12 million, a PE ratio of -2.48 and a beta of 2.75. The company has a debt-to-equity ratio of 3.25, a quick ratio of 10.03 and a current ratio of 10.42.
Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in shares of Evolus during the third quarter valued at $40,000. Paloma Partners Management Co purchased a new position in shares of Evolus during the third quarter valued at $51,000. Sei Investments Co. purchased a new position in shares of Evolus during the second quarter valued at $68,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Evolus during the third quarter valued at $72,000. Finally, Metropolitan Life Insurance Co NY purchased a new position in shares of Evolus during the first quarter valued at $83,000. Hedge funds and other institutional investors own 26.07% of the company’s stock.
About Evolus (NASDAQ:EOLS)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Story: Monthly Dividend Stocks
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.